Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135497 | 0.99 | KMT2A (0.44) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL31135500 | 0.99 | KMT2A (0.44) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL31135498 | 0.96 | KMT2A (0.46) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL28402889 | 0.91 | KMT2A (0.48) | KMT2AEPHX2FABP5FABP7CA1 | |
| Hydrochloric Acid SCHEMBL2524995 | 0.90 | KMT2A (0.47) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL887718 | 0.89 | KMT2A (0.44) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL30945377 | 0.86 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL2182540 | 0.86 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL30945369 | 0.86 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL18614183 | 0.86 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024221952-A1 | NANO-DELIVERY SYSTEM OF NUCLEOTIDE DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-10-31 | — | — | WO | claimed |
| WO-2024221952-A1 | NANO-DELIVERY SYSTEM OF NUCLEOTIDE DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-10-31 | — | — | WO | disclosed |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2012-06-21 | — | — | US | disclosed |
| EP-2453925-A2 | CYCLOSPORIN CONJUGATES | UCL Business PLC (GB) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011010084-A2 | CYCLOSPORIN CONJUGATES | UCL BUSINES PLC (GB) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | KMT2A 3065/4885EPHX2 3072/4885FABP5 3618/4885 |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | KMT2A 3078/4885EPHX2 3198/4885FABP5 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.